Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372073 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Cyclacel Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT00372073 is a Phase 2 study that was terminated before completion, run by Cyclacel Pharmaceuticals. The registered enrollment target is 187 participants.
The verdict
NCT00372073, a Phase 2 study, was terminated before completion, sponsored by Cyclacel Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).
Interventions
- DRUG placebo
- DRUG seliciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2006-08-09 |
| Est. Completion | 2009-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00372073
The ClinicalTrials.gov registry entry for NCT00372073 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00372073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00372073 about?
NCT00372073 is a clinical study titled "Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer". A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00372073?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2006-08-09. Estimated completion is 2009-04-07.
What interventions are being tested in trial NCT00372073?
The interventions under investigation include: placebo (DRUG), seliciclib (DRUG).
Who is sponsoring clinical trial NCT00372073?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.